Scientific discovery dossier · Experimental discoveries
SOCE / STIM1–ORAI1 — apoptotic resistance in pancreatic adenocarcinoma
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma
- Record type
- Preclinical scientific discovery (not a clinical trial)
- Publication
- Peer-reviewed
- DOI
- 10.1016/j.bbamcr.2014.02.012
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
- Scope / models
- Pancreas — Pankreas adenokarsinom hücre modelleri
- Molecular mechanism
- Store-operated calcium entry (SOCE) via STIM1 and ORAI1; linked to intracellular Ca²⁺ homeostasis and apoptotic threshold.
- Experimental models
- Pancreatic adenocarcinoma cell lines / in vitro SOCE measurements.
- Translational distance
- Not a validated clinical predictive test or approved drug target. Does not change surgical/adjuvant decisions.
- Research biomarker
- STIM1 / ORAI1 (SOCE)
For patients
What is being studied? In the lab, one calcium-entry pathway (SOCE) was studied in pancreatic cancer cell death resistance. This is not a patient test or drug.
Why promising? Suggested SOCE pathways may contribute to apoptotic resistance in PDAC biology, motivating translational target research.
What is not proven? Human clinical benefit; predictive use of SOCE scores in surgical oncology; safe pharmacologic inhibition.
Is this standard care today? No — this is a laboratory/scientific discovery dossier, not a treatment option.
For clinicians
DOI 10.1016/j.bbamcr.2014.02.012. SOCE_Score (neuroblastoma, TCR 2025) is a separate dossier; do not present as a PDAC clinical predictor.
Limitations: Eski preklinik kanıt; klinik validasyon yok.